Welcome to our dedicated page for 60 degrees pharmaceuticals SEC filings (Ticker: SXTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for 60 Degrees Pharmaceuticals, Inc. (SXTP) provides access to the companys official regulatory documents as filed with the U.S. Securities and Exchange Commission. 60 Degrees Pharmaceuticals, Inc. is a Delaware corporation and an emerging growth company whose common stock and warrants are listed on The Nasdaq Stock Market LLC under the symbols SXTP and SXTPW, as reflected in its registration information.
Through its periodic and current reports, investors can review how the company describes its business as a pharmaceutical company focused on developing new medicines for vector-borne disease, with an FDA-approved antimalarial product, ARAKODA ae (tafenoquine), for malaria prophylaxis. Filings such as annual and quarterly reports (Forms 10-K and 10-Q, when available) typically provide details on the companys operations, risk factors, research programs, and financial condition, including information related to its work in malaria and babesiosis.
Current reports on Form 8-K can disclose material events, including matters submitted to a vote of security holders and corporate actions. For example, an 8-K dated October 2025 reports the results of the companys 2025 Annual Stockholders Meeting, including approval of an amendment to its certificate of incorporation to permit a reverse stock split within a specified ratio range, later implemented to help address Nasdaq minimum bid price requirements.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries designed to help readers interpret the key points of complex documents, such as reverse stock split approvals, equity incentive plan amendments, and auditor ratifications. Users can also follow how the company describes its Nasdaq-listed common stock and warrants, its status as an emerging growth company, and governance decisions recorded in shareholder votes. This page updates as new filings are posted to EDGAR, offering a structured view of 60 Degrees Pharmaceuticals, Inc.s regulatory history.
60 Degrees Pharmaceuticals, Inc. files its annual report describing a specialty infectious disease business built around tafenoquine and celgosivir. The company markets Arakoda for malaria prevention and is developing tafenoquine for tick‑borne babesiosis, veterinary babesiosis and respiratory fungal and viral infections.
It strengthened its balance sheet through multiple 2024–2026 equity raises, including at‑the‑market programs and several registered direct and private warrant offerings that collectively brought in several million dollars of net proceeds. The report also details an extensive patent and trademark portfolio and ongoing clinical trials intended to support potential label expansions and new products.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to correct an error in previously disclosed share ownership for a company affiliate. A March 13, 2026 prospectus supplement had shown the affiliate as beneficially owning 21,490 shares; the correct figure is 23,367 shares. The error traces back to an incorrect total in a Form 4 dated September 15, 2025 that was carried into a December 16, 2025 Form 4 and then into the prospectus disclosure. After giving effect to the 1-for-4 reverse stock split, the corrected total number of shares beneficially owned is 16,781 instead of 15,905. The company states that no other information in the prospectus supplement is affected.
60 Degrees Pharmaceuticals amended its ATM prospectus to increase the offering capacity to $565,000. This figure gives effect to 325,200 shares previously sold for aggregate gross proceeds of $980,510.52 under the Sales Agreement with H.C. Wainwright & Co.
The supplement states shares outstanding were 2,472,949 and public float was $12,747,587 based on 2,451,459 shares held by non-affiliates and a closing price of $5.20 per share on January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026. The last reported sale price on Nasdaq was $2.91 on March 12, 2026.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to report that it obtained and filed an updated legal opinion from Sichenzia Ross Ference Carmel LLP covering shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright & Co., LLC.
The opinion, filed as Exhibit 5.1 with an associated consent in Exhibit 23.1, confirms the validity of shares that may be sold under the program and addresses related legal matters. The company states that this updated opinion does not change the existing terms of the at-the-market program.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to note that it obtained and filed an updated legal opinion from its counsel covering shares of common stock issued and sold under its existing at-the-market equity offering program with HC Wainwright & Co., LLC.
The company states that this opinion does not change the terms of the at-the-market program. Instead, it confirms the validity of shares that may be sold under the program and addresses certain legal matters related to those sales under applicable law.
60 Degrees Pharmaceuticals, Inc. amends its at-the-market program to permit the offer and sale of up to $981,000 of common stock pursuant to the Sales Agreement with H.C. Wainwright & Co., LLC, March 11, 2026.
The $981,000 capacity reflects and includes 566,067 shares previously sold for aggregate gross proceeds of $1,307,508.15 under the Sales Agreement. The company reports a public float of $11,056,547 based on 2,147,749 outstanding shares, of which 2,126,259 were held by non-affiliates as of January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026.
60 Degrees Pharmaceuticals amends its at-the-market program to register up to $1,308,000 of common stock pursuant to its September 5, 2025 Sales Agreement with H.C. Wainwright & Co., LLC.
The prospectus supplement updates the aggregate offering capacity to $1,308,000, excluding 555,593 shares previously sold for aggregate gross proceeds of $1,396,091. It states a public float of approximately $8,112,998 based on 1,581,682 shares outstanding as of January 28, 2026 and notes a one-for-four reverse stock split effective January 20, 2026. The filing cites the Form S-3 limitation that sales will not exceed one-third of public float in a 12-month period.
60 Degrees Pharmaceuticals, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). Nasdaq’s Listing Qualifications Staff confirmed the company now meets all Nasdaq Capital Market listing standards.
The company had previously received a delisting notice after its stock traded below $1.00 for 30 consecutive business days and paid a $20,000 hearing fee to appeal. With compliance restored, the February 19, 2026 Nasdaq Hearings Panel session has been cancelled, the delisting matter is closed, and the company’s common stock and warrants will continue to trade on The Nasdaq Capital Market.
60 Degrees Pharmaceuticals, Inc. (SXTP) reports that Nasdaq staff has determined to delist its common stock and warrants from The Nasdaq Capital Market. Nasdaq concluded the company failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550(a)(2), and that it is not eligible for the usual 180‑day grace period because it completed a 1‑for‑5 reverse stock split on February 24, 2025 under Listing Rule 5810(c)(3)(A)(iv). The company’s warrants are also subject to delisting under Listing Rule 5560(a) because the underlying common stock is subject to delisting. The company has paid a $20,000 hearing fee and requested an appeal to a Nasdaq hearings panel, which temporarily stays any trading suspension and the filing of a Form 25‑NSE until the panel issues its decision.
60 Degrees Pharmaceuticals, Inc. approved a reverse stock split of its common stock at a final ratio of one-for-four. The company’s stockholders approved the amendment to its Certificate of Incorporation on October 8, 2025, after a recommendation from the board of directors. The company then filed a Certificate of Amendment in Delaware on January 14, 2026, which becomes effective at 12:01 a.m. Eastern Time on January 20, 2026.
At the effective time, every four shares of issued and outstanding common stock are automatically combined and converted into one share. The company is not issuing fractional shares; any fractional amounts are rounded up to one whole share. The company also issued a press release about the reverse split on January 15, 2026, which is included as an exhibit.